Platelet-to-lymphocyte ratio and CA19-9 are simple and informative prognostic factors in patients with resected pancreatic cancer

doi:10.1016/j.hbpd.2019.03.011

Abstract
Figure/Table
References (0)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract We read with great interest the paper “Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic factor in patients with resected pancreatic cancer” published in Hepatobiliary & Pancreatic Diseases International [1] . The authors reviewed the oncological outcomes of 103 patients with pancreaticoduodenectomy, distal pancreatectomy or total pancreatectomy for pancreatic ductal adenocarcinoma (PDAC). They correlated the overall (OS) and disease specific survival (DSS) of these patients with platelet-to-lymphocyte ratio (PLR) and carbohydrate antigen 19-9 (CA19-9) level which were measured within one month prior to surgery. The authors used cutoff values of 129.1 for PLR and 74.0 U/mL for CA19-9. The worst prognosis was found for patients with high PLR and high CA19- 9 (five-year OS = 11.9%, DSS = 16.8%). An intermediate survival for patients with either one of the two factors was decreased (fiveyear OS = 31.9% and DSS = 36.4%), and the best prognosis for patients with low PLR and low CA19-9 (five-year OS = 44.0% and DSS = 47.7%).

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles in this journal by
	Negoi I
	Beuran M
	Hostiuc S
	El-Hussuna A
	de-Madaria E

Cite this article:

Negoi I, Beuran M, Hostiuc S, et al. Platelet-to-lymphocyte ratio and CA19-9 are simple and informative prognostic factors in patients with resected pancreatic cancer. Hepatobiliary Pancreat Dis Int 2019; 18(3): 203-205. DOI:10.1016/j.hbpd.2019.03.011

URL:

http://dx.doi.org/10.1016/j.hbpd.2019.03.011 OR http://www.hbpdint.com/EN/Y2019/V18/I3/203